Extrachromosomal circular DNAs in the differentiation of human bone marrow mesenchymal stem cells.
Gu Y., Song Y., Wang S., Liu J.
Laboratory Study, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40682088
- PMCID
- PMC12275313
- DOI
- 10.1186/s13287-025-04516-x
Abstract (original English)
Background Extrachromosomal circular DNA (eccDNA) plays a significant role in cancer development. However, our understanding of its role in normal cells is limited. This study aimed to explore the roles of eccDNA in the differentiation of human bone marrow mesenchymal stem cells (BMSCs). Methods Through circular DNA sequencing (Circle-seq) and computational analysis, we documented eccDNAs in human BMSCs and their differentiation into osteoblasts, adipocytes, and chondrocytes. Next, the assay for transposase-accessible chromatin with high throughput sequencing (ATAC-seq) and RNA sequencing (RNA-seq) data were integrated with Circle-seq data. The roles of phosphatidylinositol 4-kinase alpha (PI4KA) and eccDNA as functional enhancers in human BMSC differentiation were assessed in vitro. Results Our results demonstrate that eccDNA is common in human BMSCs. In the differentiated groups including osteoblasts, adipocytes and chondrocytes, eccDNA-encoded genes presented higher expression compared to the background. We found eccDNA displayed enhanced chromatin accessibility in human BMSCs, which contribute to increased transcription of genes, such as runt-related transcription factor 2 (RUNX2), a key transcription factor for BMSC osteogenesis. We further found PI4KA, an eccDNA-encoded gene, promoted osteogenic differentiation of human BMSCs via the PI3K/AKT/mTOR pathway. Finally, we dem
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.